Diffuse and Strong TTF-1 Expression Predicts Response to Pemetrexed-Based Immunochemotherapy in Advanced Lung Adenocarcinoma
Diffuse and strong TTF-1 positivity may be useful for the predictive factor for pemetrexed-based immunochemotherapy. TTF-1 staining may be desirable to develop a more optimal immunochemotherapy for lung adenocarcinoma.
Authors
- Motoko Tachihara
- Jun Yamada (ORCID: https://orcid.org/0000-0002-7595-5843)
- Natsuhiko Iwamoto
- Naoe Jimbo (ORCID: https://orcid.org/0000-0003-0423-3568)
- Yukihisa Hatakeyama (ORCID: https://orcid.org/0000-0002-3291-0637)
- Masahiro Katsurada (ORCID: https://orcid.org/0000-0003-4655-3367)
- Kanoko Matsumura
- Keiko Okuno
- Tatsunori Kiriu (ORCID: https://orcid.org/0000-0001-6877-2005)
- Kyosuke Nakata (ORCID: https://orcid.org/0000-0001-8096-865X)
- Nanami Yamasaki
Institutions
- Tambov State Technical University (RU)
- Kobe University Hospital (JP)
- Hyogo Prefectural Awaji Medical Center (JP)
- Akashi Medical Center (JP)
- Takatsuki General Hospital (JP)
- Kobe University (JP)
Publication Details
- Journal
- Cancer Management and Research
- Published
- 2025-08-01
- DOI
- https://doi.org/10.2147/cmar.s520436
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00